MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Search

Cencora Inc

Gesloten

SectorGezondheidszorg

314.13 1.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

307.55

Max

314.46

Belangrijke statistieken

By Trading Economics

Inkomsten

906M

566M

Verkoop

2.2B

86B

K/W

Sectorgemiddelde

38.442

57.05

EPS

4.08

Dividendrendement

0.69

Winstmarge

0.659

Werknemers

47,000

EBITDA

858M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+32.75% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.69%

2.52%

Volgende Winsten

6 mei 2026

Volgende dividenddatum

1 jun 2026

Volgende Ex Dividend datum

15 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-8.4B

62B

Vorige openingsprijs

312.74

Vorige sluitingsprijs

314.13

Nieuwssentiment

By Acuity

6%

94%

4 / 349 Rangschikking in Healthcare

Cencora Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 mrt 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Nike, RH, NCino

31 mrt 2026, 22:35 UTC

Winsten

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr 2026, 00:00 UTC

Acquisities, Fusies, Overnames

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mrt 2026, 23:50 UTC

Acquisities, Fusies, Overnames

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mrt 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mrt 2026, 23:33 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mrt 2026, 23:21 UTC

Winsten

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mrt 2026, 23:14 UTC

Marktinformatie
Winsten

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mrt 2026, 23:12 UTC

Marktinformatie

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss Widens >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mrt 2026, 21:46 UTC

Acquisities, Fusies, Overnames

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mrt 2026, 21:36 UTC

Marktinformatie

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mrt 2026, 21:33 UTC

Winsten

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mrt 2026, 21:32 UTC

Winsten

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mrt 2026, 21:28 UTC

Winsten

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mrt 2026, 21:26 UTC

Winsten

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mrt 2026, 21:25 UTC

Winsten

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mrt 2026, 21:24 UTC

Marktinformatie
Winsten

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mrt 2026, 21:22 UTC

Winsten

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mrt 2026, 21:22 UTC

Winsten

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mrt 2026, 21:21 UTC

Winsten

Nike's Digital Channel Still Too Promotional, CFO Says

31 mrt 2026, 21:20 UTC

Winsten

Nike CEO: Converse Remains Important to Portfolio

Peer Vergelijking

Prijswijziging

Cencora Inc Prognose

Koersdoel

By TipRanks

32.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 411.44 USD  32.75%

Hoogste 440 USD

Laagste 380 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cencora Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Sentiment

By Acuity

4 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat